Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IVDIV
ADC Name
TQB2102
Synonyms
TQB 2102; TQB-2102; TQB2102
   Click to Show/Hide
Organization
Nanjing Shunxin Pharmaceutical Co., Ltd.; Sino Biopharmaceutical Ltd.
Drug Status
Phase 2
Indication
In total 4 Indication(s)
Breast cancer
Phase 3
Clinical Trial
Biliary tract cancer
Phase 2
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
5.8
Structure
Antibody Name
Undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
  Antigen Info 
Payload Name
2-DDDX-d
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
  Linker Info 
Conjugate Type
Random Cysteines
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05735496
Phase 1
A phase 1 study of TQB2102 injection in patients with advanced cancers.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05735496  Clinical Status Phase 1
Clinical Description A phase 1 study of TQB2102 injection in patients with advanced cancers.
References
Ref 1 A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers